Clark Chen1, Ian Lee2, Claudio Tatsui3, Theresa Elder4, Andrew E Sloan5,6. 1. University of Minnesotta, Minneapolis, USA. 2. Henry Ford Hospitals, Detroit, USA. 3. MD Anderson Cancer Center, Houston, USA. 4. Seidman Cancer Center, University Hospitals, Shaker Heights, USA. 5. Seidman Cancer Center, University Hospitals, Shaker Heights, USA. Andrew.Sloan@UHHospitals.org. 6. Case Comprehensive Cancer Center, Cleveland, USA. Andrew.Sloan@UHHospitals.org.
Abstract
INTRODUCTION: Laser Interstitial Thermotherapy (LITT; also known as Stereotactic Laser Ablation or SLA), is a minimally invasive treatment modality that has recently gained prominence in the treatment of malignant primary and metastatic brain tumors and radiation necrosis and studies for treatment of spinal metastasis has recently been reported. METHODS: Here we provide a brief literature review of the various contemporary uses for LITT and their reported outcomes. RESULTS: Historically, the primary indication for LITT has been for the treatment of recurrent glioblastoma (GBM). However, indications have continued to expand and now include gliomas of different grades, brain metastasis (BM), radiation necrosis (RN), other types of brain tumors as well as spine metastasis. LITT is emerging as a safe, reliable, minimally invasive clinical approach, particularly for deep seated, focal malignant brain tumors and radiation necrosis. The role of LITT for treatment of other types of tumors of the brain and for spine tumors appears to be evolving at a small number of centers. While the technology appears to be safe and increasingly utilized, there have been few prospective clinical trials and most published studies combine different pathologies in the same report. CONCLUSION: Well-designed prospective trials will be required to firmly establish the role of LITT in the treatment of lesions of the brain and spine.
INTRODUCTION: Laser Interstitial Thermotherapy (LITT; also known as Stereotactic Laser Ablation or SLA), is a minimally invasive treatment modality that has recently gained prominence in the treatment of malignant primary and metastatic brain tumors and radiation necrosis and studies for treatment of spinal metastasis has recently been reported. METHODS: Here we provide a brief literature review of the various contemporary uses for LITT and their reported outcomes. RESULTS: Historically, the primary indication for LITT has been for the treatment of recurrent glioblastoma (GBM). However, indications have continued to expand and now include gliomas of different grades, brain metastasis (BM), radiation necrosis (RN), other types of brain tumors as well as spine metastasis. LITT is emerging as a safe, reliable, minimally invasive clinical approach, particularly for deep seated, focal malignant brain tumors and radiation necrosis. The role of LITT for treatment of other types of tumors of the brain and for spine tumors appears to be evolving at a small number of centers. While the technology appears to be safe and increasingly utilized, there have been few prospective clinical trials and most published studies combine different pathologies in the same report. CONCLUSION: Well-designed prospective trials will be required to firmly establish the role of LITT in the treatment of lesions of the brain and spine.
Authors: Gazanfar Rahmathulla; Pablo F Recinos; Kambiz Kamian; Alireza M Mohammadi; Manmeet S Ahluwalia; Gene H Barnett Journal: Oncology Date: 2014-07-03 Impact factor: 2.935
Authors: Michael E Ivan; Alireza M Mohammadi; Nicoleta De Deugd; Joshua Reyes; Gregor Rodriguez; Ashish Shah; Gene H Barnett; Ricardo J Komotar Journal: Neurosurgery Date: 2016-12 Impact factor: 4.654
Authors: James Wright; Jessey Chugh; Christina Huang Wright; Fernando Alonso; Alia Hdeib; Haley Gittleman; Jill Barnholtz-Sloan; Andrew E Sloan Journal: Neurosurg Focus Date: 2016-10 Impact factor: 4.047
Authors: Robert C Rennert; Usman Khan; Stephen B Tatter; Melvin Field; Brian Toyota; Peter E Fecci; Kevin Judy; Alireza M Mohammadi; Patrick Landazuri; Andrew Sloan; Eric Leuthardt; Clark C Chen Journal: World Neurosurg Date: 2018-05-14 Impact factor: 2.104
Authors: Alireza M Mohammadi; Ammar H Hawasli; Analiz Rodriguez; Jason L Schroeder; Adrian W Laxton; Paul Elson; Stephen B Tatter; Gene H Barnett; Eric C Leuthardt Journal: Cancer Med Date: 2014-05-09 Impact factor: 4.452
Authors: Isabela Peña Pino; Jun Ma; Yusuke S Hori; Elena Fomchenko; Kathryn Dusenbery; Margaret Reynolds; Christopher Wilke; Jianling Yuan; Ethan Srinivasan; Matthew Grabowski; Peter Fecci; Evidio Domingo-Musibay; Naomi Fujioka; Gene H Barnett; Veronica Chang; Alireza M Mohammadi; Clark C Chen Journal: J Neurooncol Date: 2022-01-10 Impact factor: 4.130
Authors: Birra R Taha; Christian R Osswald; Matthew Rabon; Carolina Sandoval Garcia; Daniel J Guillaume; Xiao Wong; Andrew S Venteicher; David P Darrow; Michael C Park; Robert A McGovern; Cornelius H Lam; Clark C Chen Journal: World Neurosurg X Date: 2021-12-16
Authors: Nadine Heßler; Stephanie T Jünger; Anna-Katharina Meissner; Martin Kocher; Roland Goldbrunner; Stefan Grau Journal: BMC Cancer Date: 2022-03-15 Impact factor: 4.430